Rebeca Higino Becker
Research Subjects
Rebeca Higino Becker has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Ramacciotti
Science Valley Research Institute, Brasil; Loyola University Medical Center, EUA
2 shared publications - Flávia Magalhães Silveira Magella Oliveira
Instituto de Infectologia Emílio Ribas
2 shared publications - Samantha Neves
Santa Casa de Sao Paulo School of Medical Sciences
2 shared publications - Alexandre Fioranelli
Hospital Israelita Albert Einstein
1 shared publication - Ariadne Ribeiro Negrão
Vascular Surgery Department, Faculdade de Ciências Médicas da Santa Casa de São Paulo
1 shared publication - Camilla Moreira Ribeiro
Science Valley Research Institute
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250108
Evaluation of a clinical score to predict post-sclerotherapy hyperpigmentation compared with the Skin Hyperpigmentation Index: a prospective Skin Code study
Post-sclerotherapy hyperpigmentation (PSH) is a common complication following sclerotherapy for telangiectasias and reticular veins. However, tools for pre-procedural prediction of PSH are limited, making pre-treatment identification of patients at greater risk a challenge. This research aimed to evaluate a clinical scoring system (Skin Code Score) designed to estimate the individual risk of PSH. A prospective, single-center, single-arm study was conducted. Adult female patients with telangiectasias and reticular veins were treated and evaluated for pigmentation risk using the Skin Code Score (range, 2-12 points). Hyperpigmentation was assessed at baseline and on day 30 by in-person evaluation performed by one vascular surgeon, complemented by photographic analysis conducted independently by two other vascular surgeons and one dermatologist. Skin Hyperpigmentation Index (SHI) measurements were used for objective correlation with the Skin Code Score. The Skin Code Score showed strong interobserver agreement and reproducibility (κ ≥ 0.85). Diagnostic accuracy ranged from 82.8% to 94.7% among evaluators. A score of 12 predicted PSH in up to 99.8% of cases, while a score of 8 indicated a probability of approximately 76%. The study was limited by a small sample size and its single-center design; a proportion of the assessments were conducted by photographic analysis. It is concluded that the Skin Code Score is a simple and reproducible tool for predicting PSH and could assist clinicians with pre-procedural risk stratification, patient counseling, and clinical decision-making.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250108
Open AccessEvaluation of a clinical score to predict post-sclerotherapy hyperpigmentation compared with the Skin Hyperpigmentation Index: a prospective Skin Code study
Post-sclerotherapy hyperpigmentation (PSH) is a common complication following sclerotherapy for telangiectasias and reticular veins. However, tools for pre-procedural prediction of PSH are limited, making pre-treatment identification of patients at greater risk a challenge. This research aimed to evaluate a clinical scoring system (Skin Code Score) designed to estimate the individual risk of PSH. A prospective, single-center, single-arm study was conducted. Adult female patients with telangiectasias and reticular veins were treated and evaluated for pigmentation risk using the Skin Code Score (range, 2-12 points). Hyperpigmentation was assessed at baseline and on day 30 by in-person evaluation performed by one vascular surgeon, complemented by photographic analysis conducted independently by two other vascular surgeons and one dermatologist. Skin Hyperpigmentation Index (SHI) measurements were used for objective correlation with the Skin Code Score. The Skin Code Score showed strong interobserver agreement and reproducibility (κ ≥ 0.85). Diagnostic accuracy ranged from 82.8% to 94.7% among evaluators. A score of 12 predicted PSH in up to 99.8% of cases, while a score of 8 indicated a probability of approximately 76%. The study was limited by a small sample size and its single-center design; a proportion of the assessments were conducted by photographic analysis. It is concluded that the Skin Code Score is a simple and reproducible tool for predicting PSH and could assist clinicians with pre-procedural risk stratification, patient counseling, and clinical decision-making.
- 4 September 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (5) , 410-418
Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)
Background: Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire. Results: Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002). Conclusion: Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.
- 4 September 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (5) , 410-418
Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)
Background: Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire. Results: Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002). Conclusion: Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.